6 results about "Bone Tuberculosis" patented technology

This invention belongs to the field of traditional Chinese medicine external preparation technology, specifically providing a traditional Chinese medicine ointment for treating chronic osteomyelitis, bone tuberculosis, and persistent sinus tracts, as well as its preparation method. The traditional Chinese medicine ointment provided by this invention comprises 3-10 parts of *Achyranthes bidentata*, 5-15 parts of dried ginger, 0.3-1 part of red mercury sulfate, 20-50 parts of calcined gypsum, 4-12 parts of gecko, 5-15 parts of buffalo hide, and 40-100 parts of medicinal ointment base. This invention selects *Achyranthes bidentata*, red mercury sulfate, calcined gypsum, gecko, dried ginger, and buffalo hide as the main ingredients, achieving a combination of warming and cooling properties, and a tonifying and purging effect. It can effectively clear deep pus, necrotic tissue, and dead bone, while also warming and unblocking meridians, improving local blood circulation, promoting wound healing, and reducing the irritation of the medication.

The invention relates to the technical field of artificial intelligence and machine learning, discloses a method for establishing an identification model of bone tuberculosis (STB) and suppurative bone infection (PSI) based on deep learning, and provides a novel interpretable deep learning model based on a Transform architecture, and the STB and the PSI are distinguished by using a diagnostic tag confirmed by metagenome next-generation sequencing. The TabPFN model provided by the invention not only shows strong diagnosis accuracy, but also has interpretability of early-stage STB recognition by utilizing the diagnosis tag confirmed by mNGS and common serological biomarkers, and provides instant early-stage diagnosis decision support for clinicians. According to the method, the TabPFN model is applied to diagnosis of the spinal bone tuberculosis for the first time, an efficient and accurate tool is provided, and a solid foundation is laid for future artificial intelligence auxiliary clinical diagnosis research.

The invention relates to a Chinese and western medicine composition for treating bone tuberculosis, a Chinese and western medicine preparation, a preparation method and application. The composition is prepared from the following components in parts by weight: 5 to 15 parts of radix angelicae sinensis, 3 to 10 parts of rhizoma atractylodis macrocephalae, 5 to 10 parts of radix codonopsis, 5 to 10 parts of poria cocos, 5 to 15 parts of raw rhizoma atractylodis, 5 to 10 parts of radix angelicae pubescentis, 5 to 10 parts of rhizoma seu radix notopterygii, 1 to 5 parts of herba asari, 5 to 10 parts of flos carthami, 3 to 10 parts of radix polygalae, 3 to 10 parts of radix platycodonis, 5 to 10 parts of radix saposhnikoviae, 0.3 to 0.7 part of borneol, 3 to 5 parts of spica prunellae, 3 to 5 parts of rhizoma chuanxiong, 5 to 10 parts of ramie and 10 to 15 parts of vitamin B6. The medicine is applied to treatment of various bone tuberculosis. The Chinese and western medicine composition provided by the invention is simple and proper in compatibility, and has the effect of treating extremely high bone tuberculosis through clinical examination for many years.

The application provides a combination of flurbiprofen axetil and oxeladin fumarate for postoperative analgesia and immune protection of patients with bone tuberculosis. Specifically, the application provides use of flurbiprofen axetil and oxeladin fumarate for preparing an analgesic drug for patients with bone tuberculosis surgery. The application also provides a pharmaceutical composition comprising flurbiprofen axetil and oxeladin fumarate, an analgesic drug kit, a pharmaceutical use and an analgesic method for patients with bone tuberculosis surgery. In the application, the combination of flurbiprofen axetil and oxeladin fumarate produces a synergistic analgesic effect, effectively solves the problem of poor analgesic effect in some patients, reduces the single drug dose and adverse reactions, and is beneficial to immune regulation of patients with bone tuberculosis surgery and accelerates the recovery of patients. The application provides a safer and more effective analgesic method and analgesic drug for patients with bone tuberculosis surgery, and the analgesic method and analgesic drug have a protective effect on the immune function of patients.

The invention provides a flurbiprofen axetil and oxiselidine fumarate combination scheme for postoperative analgesia and immune protection of bone tuberculosis patients. Specifically, the invention provides application of flurbiprofen axetil and oxiselidine fumarate, and the flurbiprofen axetil and oxiselidine fumarate are used for preparing analgesic drugs for bone tuberculosis operation patients. The invention also provides a pharmaceutical composition containing flurbiprofen axetil and oxiselidine fumarate, an analgesic drug kit, pharmaceutical application and an analgesic method for bone tuberculosis surgical patients. According to the invention, the flurbiprofen axetil and the oxiselidine fumarate are combined for use to generate a synergistic analgesic effect, so that the problem of poor analgesic effect of part of patients can be effectively solved, and the combined use reduces the single dosage and adverse reaction, is beneficial to immunoregulation of bone tuberculosis surgical patients and accelerates the rehabilitation of the patients. The analgesic method and the analgesic drug which are safer and more effective and have a protection effect on the immune function of a patient are provided for the patient with the bone tuberculosis operation.

The invention belongs to the technical field of biological medicine, provides a method for constructing a biosafety mouse bone tuberculosis model based on mycobacterium smegmatis, and evaluates that under the condition of a standard biosafety level (BSL)-1, the mycobacterium smegmatis induces local and disseminated bone infection through three infection pathways, and the bone tuberculosis model has the advantages that the bone tuberculosis is induced by the mycobacterium smegmatis through three infection pathways; results show that the mouse model for intracentral injection administration of the three infection pathways is closer to the latent progress of human bone tuberculosis. The mouse model based on the mycobacterium smegmatis provides a simple and reliable platform related to immunopathology for exploring host-pathogen dynamics, immunologically-driven bone destruction and early treatment tests.